Allergy Therapeutics plc (AGY.L) LSE

Currency In GBp

AD

Valuation

Market Cap378.93M
Enterprise Value426.23M
P/E Ratio-6.79
PEG Ratio0.48
Price/Sales Ratio5.91
Price/Book Ratio82.63
Enterprise/Revenue6.2
Enterprise/EBITDA-10.86

Fiscal Year

Fiscal YearJune 30, 2025
Most Recent QuarterDecember 31, 2025

Profitability

Profit Margin-0.85
Operating Margin-0.6
AD

Management Effectiveness

Return On Assets-0.69
Return On Equity4.09

Income Statement

Revenue55.04M
Revenue/Share0.01
Gross Profit25.13M
EBITDA-29.43M
Net Income-40.13M
Diluted EPS-0.01

Balance Sheet

Total Cash10.08M
Total Cash/Share0
Total Debt26.75M
Total Debt/Equity6.3
Current Ratio1.13
Book Value Per Share0

Price History

52-Week Change-16
52-Week High12.1
52-Week Low6
Moving Average 50 Days8.4
Moving Average 200 Days9.87

Statistics

Average Volume226,581
Shares Outstanding5.04B
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor63:29
Last Split DateSeptember 28, 2023
AD